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44 Vancomycin is one of the most commonly prescribed antibiotics and has been a 
45 mainstay of therapy for patients with suspected or documented antibiotic-resistant gram-
46 positive infections for decades.  Despite its frequent use, optimal and safest dosing remains 
47 controversial. In 2009, consensus guidelines were developed to facilitate vancomycin dosing 
48 and monitoring.  For serious methicillin-resistant Staphylococcus aureus (MRSA) infections, the 















This article is protected by copyright. All rights reserved
50 (PK/PD) target for vancomycin is an area-under-the-concentration-time curve to minimum 
51 inhibitory concentration ratio (AUC/MIC) ≥400.  As AUCs are not routinely determined in clinical 
52 practice, the 2009 consensus guidelines recommended trough monitoring and maintaining 
53 trough concentrations between 15-20 mg/L as a surrogate marker of the AUC/MIC (target 400 
54 mg*h/L) for ease of managing therapy and simplifying dose adjustments and monitoring.  
55 With widespread adoption of these recommendations into clinical practice, there have 
56 been numerous reports of increased nephrotoxicity, consistently in both adults and children, 
57 associated with maintaining vancomycin troughs between 15-20 mg/L without any notable 
58 improvement in outcomes.  Studies indicated that there is a high degree of inter-individual 
59 variability between a measured trough concentration and the actual daily AUC value.  A trough 
60 value of 15-20 mg/L will almost always ensure a daily AUC in excess of 400 mg*L/h.  However, 
61 there is considerable variability in the upper range of AUC values and most patients will have a 
62 daily AUC in excess of 600 mg*L/h.  Patients with daily AUCs in excess of 600 mg*L/h were 
63 reported to be at an increased risk of vancomycin-associated nephrotoxicity across a number of 
64 studies.  Furthermore, several studies indicate that AUC-guided dosing relative to trough-based 
65 monitoring is associated with less nephrotoxicity and comparable outcomes.  
66 This Vancomycin Consensus Guideline for dosing and monitoring vancomycin is an 
67 updated revision to the 2009 guidelines and was developed by the American Society of Health-
68 Systems Pharmacists, Infectious Diseases Society of America, Pediatric Infectious Diseases 
69 Society and the Society of Infectious Diseases Pharmacists vancomycin guidelines committee.  
70 Based on best available evidence, these guidelines conclude that AUC-guided dosing and 
71 monitoring is the most accurate and safest way to optimize vancomycin dosing.  For AUC-
72 guided dosing, the vancomycin minimum inhibitory concentration by broth microdilution 
73 (MICBMD) should be assumed to be 1 mg/L since the vancomycin MICBMD for MRSA is 1 mg/L or 
74 less at most institutions and measurement of MIC values is imprecise with a range of accuracy 
75 of ± 1 log2 dilutions. There is a high degree of variability between commercially available MIC 
76 testing methods relative to the MICBMD method (see MIC Susceptibility Testing section of full 
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78 at most institutions, it further supports the use of AUC (assuming a MICBMD of 1 mg/L) to guide 
79 vancomycin empiric dosing.
80 In both adults and pediatrics, daily AUCs should be maintained between 400 and 600 
81 mg*hr/L to achieve clinical efficacy while improving patient safety for patients with suspected 
82 or definitive serious invasive MRSA infections.  Given the importance of early, appropriate 
83 therapy, targeted AUC exposures should be achieved early during the course of therapy, 
84 preferably within the first 24 to 48 hours.  Use of loading doses (20-35 mg/kg based on actual 
85 body weight) should be considered in patients who are critically-ill or in the intensive care unit, 
86 requiring renal replacement therapy, or receiving continuous infusion therapy of vancomycin.  
87 Since the estimated volume of distribution for vancomycin does not increase in a proportionate 
88 manner with actual body weight, a vancomycin loading dose of 20-25 mg/kg using actual body 
89 weight with a maximum of 3000 mg may be considered in obese adult patients with serious 
90 infections. 
91 While AUC monitoring was perceived to be a cumbersome and intensive process in the 
92 past, it is possible to accurately estimate the AUC with limited PK sampling. One such approach 
93 involves the use of Bayesian software programs to estimate the vancomycin AUC value with 
94 minimal PK sampling (i.e., one or two vancomycin concentrations) and provide AUC-guided 
95 dosing recommendations in real-time.  An alternative approach involves use of two 
96 concentrations (peak and trough) and simple analytic PK equations to estimate AUC values.  
97 The committee still endorses administering vancomycin as conventional intermittent doses but 
98 recognized that continuous infusion may be a reasonable alternative to conventional 
99 intermittent infusion dosing when the AUC target cannot be achieved.
100 Specific details for each section of the document, including references, can be found in 
101 the primary publication.1   Recommendations for dosing in patients with obesity, patients on 
102 renal replacement therapy, and pediatrics are provided in this consensus guideline update.  It is 
103 important to recognize that almost all the data available on vancomycin PK/PD and 
104 toxicodynamics have been derived from patients who have been treated for serious MRSA 
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106 invasive infections or other bacterial species susceptible to vancomycin.  The recommendations 
107 in this document should not circumvent sound clinical judgement in managing patients who 
108 require vancomycin therapy.  
109
110 Table 1.  Grading System for Recommendations Based on Quality of Evidence
Category and Grade Definition 
Strength of recommendation 
 A 
Good evidence to support a recommendation 
for or against use 
 B 
Moderate evidence to support a 
recommendation for or against use 
 C Poor evidence to support a recommendation 
Quality of evidence 
 I 
Evidence from 1 or more properly 
randomized controlled trials 
 II 
Evidence from 1 or more well-designed 
clinical trials, without randomization; from 
cohort or case-controlled analytic studies 
(preferably from >1 center); from multiple 
time-series; or from dramatic results from 
uncontrolled experiments 
 III 
Evidence from opinions of respected 
authorities, based on clinical experience, 
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committees 
111 Adapted from the Canadian Task Force on the Periodic Health Examination[2]
112
113 Table 2. Primary Recommendations for Vancomycin Dosing and Therapeutic Drug Monitoring
114
A.  ADULTS AND PEDIATRICS
1. In patients with suspected or definitive serious MRSA infections, an individualized target of the 
AUC/MICBMD ratio of 400 to 600 (assuming a vancomycin MICBMD of 1 mg/L) should be advocated 
to achieve clinical efficacy while improving patient safety (A-II). 
2. When transitioning to AUC/MIC monitoring, clinicians should conservatively target AUCs for 
patients with suspected or documented serious infections due to MRSA assuming a vancomycin 
MICBMD of 1 mg/L or less at most institutions. Given the importance of early, appropriate therapy, 
vancomycin targeted exposure should be achieved early during the course of therapy, preferably 
within the first 24 to 48 hours (A-II).  As such, the use of Bayesian-derived AUC monitoring may 
be prudent in these cases since it doesn’t require steady-state serum vancomycin concentrations 
to allow for early assessment of AUC target attainment.
3. Trough only monitoring, with target between 15–20 mg/L, is no longer recommended based on 
efficacy and nephrotoxicity data in patients with serious infections due to MRSA (A-II).  There is 
insufficient evidence to provide recommendations on whether trough only or AUC-guided 
vancomycin monitoring should be used among patients with non-invasive MRSA or other 
infections.  
4. Vancomycin monitoring is recommended for patients receiving vancomycin for serious MRSA 
infections to achieve sustained targeted AUC (assuming a MICBMD of 1 mg/L, unless it is known to 
be greater or less than 1 mg/L by BMD).  Independent of MRSA infection, vancomycin monitoring 















This article is protected by copyright. All rights reserved
receiving concurrent nephrotoxins), patients with unstable (i.e., deteriorating or significantly 
improving) renal function, and those receiving prolonged courses of therapy (more than three to 
five days).  We suggest the frequency of monitoring be based on clinical judgement; frequent or 
daily monitoring may be prudent for hemodynamically unstable patients (e.g., end stage renal 
disease) and once-weekly monitoring for hemodynamically stable patients (B-II). 
5. Based on current national vancomycin susceptibility surveillance data, under most circumstances 
for empiric dosing, the vancomycin MIC should be assumed to be 1 mg/L. When the MICBMD is > 1 
mg/L, the probability of achieving an AUC/MIC ≥ 400 target is unlikely with conventional dosing; 
higher doses may risk unnecessary toxicity and the decision to change therapy should be based 
on clinical judgement. In addition, when MICBMD < 1 mg/L, we do not recommend decreasing the 
dose to achieve the AUC/MIC target.  It is important to note the limitations in automated 
susceptibility testing methods, including the lack of precision and variability in MIC results 
depending on method used (B-II).
6. The pharmacokinetics of continuous infusion suggest that such regimens may be a reasonable 
alternative to conventional intermittent infusion dosing when the AUC target cannot be achieved 
(B-II).  
7. Incompatibility with vancomycin and other drugs commonly co-administered in the ICU requires 
the use of independent lines or multiple-catheters when vancomycin is being considered for 
continuous infusion (A-III).
B.  ADULTS
8. Given the narrow vancomycin AUC range for therapeutic effect and minimal acute kidney injury 
(AKI), the most accurate and optimal way to manage vancomycin dosing should be through AUC-
guided dosing and monitoring (A-II).  We recommend to accomplish this in one of two ways.
a. One approach relies on the collection of two concentrations (obtained near steady-state, 
post-distributional peak concentration at 1-2 hours after infusion and trough at end of 
dosing interval) preferably but not required during the same dosing interval (if possible) 
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b. The preferred approach to monitor AUC involves the use of Bayesian software programs, 
embedded with a PK model based on richly sampled vancomycin data as the Bayesian 
prior, to optimize the delivery of vancomycin based on the collection of one or two 
vancomycin concentrations, with at least one trough.  It is preferred to obtain two PK 
samples (i.e., 1-2 hours post infusion and at end of dosing interval) to estimate the AUC 
with the Bayesian approach (A-II).  A trough concentration alone may be sufficient to 
estimate the AUC with the Bayesian approach in some patients, but more data are 
needed across different patient populations to confirm viability of using trough only data 
(B-II).  
9. Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an 
intermittent infusion are recommended for most patients with normal renal function when 
assuming MICBMD of 1 mg/L (A-II).  In patients with normal renal function, these doses may not 
achieve therapeutic AUC/MIC target when the MIC is 2 mg/L. 
10. Continuous Infusion: Based on current available data, a loading dose of 15-20mg/kg, followed by 
daily maintenance CI of 30-40mg/kg up to 60mg/kg, to achieve target steady-state concentration 
of 20-25mg/L may be considered for critically-ill patients (B-II).   AUC24 can be simply calculated 
when multiplying steady-state concentration (i.e., desired therapeutic range of 20-25 mg/L 
throughout entire dosing interval) by a factor of 24 (B-II).  Attaining the desired drug exposure 
may be more readily accomplished given the ease of sampling time and dosage adjustment by 
changing the rate of infusion which is a highly desirable feature in critically-ill patients (B-II).
11. The risk of developing nephrotoxicity with continuous infusion appears to be similar or lower 
compared to intermittent dosing when targeting steady-state concentration 15-25 mg/L and 
trough 10-20 mg/L, respectively (B-II).  Definitive studies are needed to compare drug exposure 
based on measured AUC24 and factors that predispose to development of nephrotoxicity such as 
receipt of concomitant nephrotoxins, diuretics, and/or vasopressor therapy in patients receiving 
continuous infusion vs. intermittent infusion of vancomycin. 
12. In order to achieve rapid attainment of targeted concentrations in critically-ill patients with 
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considered for intermittent administration of vancomycin (B-II).  Loading doses should be based 
on actual body weight and not exceed 3000 mg.  More intensive and early therapeutic 
monitoring should also be performed in obese patients (B-II).
13. Adult Obesity: A vancomycin loading dose of 20-25 mg/kg using actual body weight with a 
maximum of 3000 mg may be considered in obese adult patients with serious infections (B-II). 
Empiric maintenance doses for most obese patients usually do not exceed 4500 mg/day, 
depending on their renal function (B-II).  Early and frequent monitoring of AUC exposure is 
recommended for dose adjustment, especially when empiric doses exceed 4000 mg/day (A-II).
14. Intermittent Hemodialysis: Since efficacy data are unavailable for AUC < 400 mg*hr/L, monitoring 
based on pre-dialysis serum concentrations and extrapolating these values to estimate AUC is 
most practical. Maintaining pre-dialysis concentrations between 15 and 20 mg/L are likely to 
achieve the AUC of 400-600 mg*hr/L in the previous 24 hours (C-III).  Pre-dialysis serum 
concentration monitoring should be performed not less than weekly and should drive 
subsequent dosing rather than a strict weight-based recommendation, although these 
recommended doses provide a useful starting point until serum concentrations have been 
determined (B-II).  
15. Hybrid Dialysis Therapies (e.g. Slow-Low Efficiency Dialysis [SLED]): Loading doses of 20-25 mg/kg 
actual body weight should be used, recognizing that these hybrid dialysis therapies efficiently 
remove vancomycin (B-III). Initial doses should not be delayed to wait for a dialysis treatment to 
end. Maintenance doses of 15 mg/kg should be given after hybrid hemodialysis ends or during 
the final 60-90 minutes of dialysis, as is done with standard hemodialysis (B-III). Concentration 
monitoring should guide further maintenance doses.  
16. Continuous Renal Replacement Therapies (CRRT): Loading doses of 20-25 mg/kg by actual body 
weight should be used in patients receiving CRRT at conventional, KDIGO-recommended effluent 
rates of 20-25 mL/kg/hr (B-II).  Initial maintenance dosing for CRRT with effluent rates of 20-25 
mL/kg/hr should be 7.5-10 mg/kg every 12 hours (B-II).  Maintenance dose and dosing interval 
should be based on serum concentration monitoring which should be conducted within the first 
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reduced as patients become euvolemic and drug Vd decreases. The use of continuous infusion 
vancomycin in patients receiving CRRT appears to be growing, and could be used in place of 
intermittent vancomycin dosing, especially when high CRRT ultrafiltrate/dialysate flow rates are 
employed (B-II).  
C.  PEDIATRICS
17. Based on an AUC target of 400 mg*hr/L (but potentially up to 600 mg*hr/L assuming MIC of ≤ 1 
mg/L) from adult data, the initial recommended vancomycin dosage for children with normal 
renal function and suspected serious MRSA infections is 60 to 80 mg/kg/day, divided every 6 to 8 
hour, for children ages 3 months and older (A-II). 
18. The maximum empiric daily dose is usually 3600 mg/day in children with adequate renal function 
(C-III).   Most children generally should not require more than 3000 mg/day and doses should be 
adjusted based on observed concentrations to achieve the AUC/MIC target.  Early monitoring of 
observed concentrations is recommended when doses exceed 2000 to 3000 mg/day (A-III).  
Furthermore, close monitoring of observed concentrations and renal function is prudent in 
patients with poor or augmented renal clearance as resolution of their renal function may occur 
within the first five days of therapy.  
19. AUC-guided therapeutic monitoring for vancomycin, preferably with Bayesian estimation, is 
suggested for all pediatric age groups, based on developmental changes of vancomycin CL 
documented from the newborn to the adolescent.  Based on current available data, the 
suggestion for AUC-guided monitoring in pediatrics aligns with the approach for adults, including 
the application of Bayesian estimation for one trough concentration, or first-order PK equations 
with two concentrations (B-II).  The Bayesian AUC-guided dosing strategy may be an optimal 
approach to individualize vancomycin therapy in pediatrics since it can incorporate varying ages, 
weights, and renal function.  Both serum concentrations of vancomycin and renal function 
should be monitored since vancomycin CL and creatinine CL are not always well correlated in 
pediatrics.  Furthermore, aggressive dosing to maintain target AUC exposure and decrease the 
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20. Therapeutic monitoring may begin within 24 to 48 hours of vancomycin therapy for serious 
MRSA infections in children, as in adults (B-III).  Any delay in therapeutic monitoring should be 
based on severity of infection and clinical judgment.  Dosing adjustment should be made for 
those with renal insufficiency, obesity, or for those receiving concurrent nephrotoxic drug 
therapy.   Following the initial dose, dosing adjustment is important for those with acute renal 
insufficiency, but subsequent adjustment (particularly within the first 5 days of therapy) may be 
necessary for those experiencing recovery of renal function.  Sustained or subsequent decreases 
in dosage may be needed, particularly for those with chronic renal insufficiency and those 
receiving concurrent nephrotoxic drug therapy (B-III).  
21. Vancomycin exposure may be optimally maintained below the thresholds for AUC of 800 
mg*hr/L and trough concentrations of 15 mg/L to minimize AKI (B-II).  The safety of vancomycin 
above 80 mg/kg/day has not been prospectively evaluated.  Avoiding vancomycin doses  100 
mg/kg/day is suggested since they are likely to surpass these thresholds (B-III).
22. Insufficient data exist on which to base a recommendation for a loading dose among the non-
obese pediatric population.  Loading doses from adult studies may be considered, but further 
studies are needed to elucidate the appropriate dose for the various pediatric populations from 
the neonate to adolescent (C-III).
23. Pediatric Obesity: Data suggest that obese children are likely to have vancomycin exposures that 
may be statistically greater than normal weight children when doses are calculated on a mg/kg 
basis, but these differences are not known to be of sufficient clinical importance to suggest 
different mg/kg empiric vancomycin dosages in obese children at this time.  Similar to non-obese 
children, obese children < 12 years old, compared with those ≥ 12 years, may require higher 
mg/kg dose (B-II).  
24. Pediatric Obesity: Therapeutic monitoring is likely to be of particular value in obese children, 
both for therapeutic response and the risk of AKI.  The specific recommendations for therapeutic 
monitoring in non-obese children may also apply for obese children (B-II).  A loading dose of 20 
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25. Neonates: Doses recommended to achieve an AUC of 400 mg*hr/L (assuming an MIC of 1 mg/L) 
in neonates and infants up to 3 months old range from 10 to 20 mg/kg every 8 to 48 hours, 
depending on post-menstrual age, weight and SCr (A-II).   
115
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Category and Grade  Definition  
Strength of recommendation   
 A  
Good evidence to support a recommendation 
for or against use  
 B  
Moderate evidence to support a 
recommendation for or against use  
 C  Poor evidence to support a recommendation  
Quality of evidence   
 I  
Evidence from 1 or more properly 
randomized controlled trials  
 II  
Evidence from 1 or more well-designed 
clinical trials, without randomization; from 
cohort or case-controlled analytic studies 
(preferably from >1 center); from multiple 
time-series; or from dramatic results from 
uncontrolled experiments  
 III  
Evidence from opinions of respected 
authorities, based on clinical experience, 
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A.  ADULTS AND PEDIATRICS 
1. In patients with suspected or definitive serious MRSA infections, an individualized target of the 
AUC/MICBMD ratio of 400 to 600 (assuming a vancomycin MICBMD of 1 mg/L) should be advocated 
to achieve clinical efficacy while improving patient safety (A-II).  
2. When transitioning to AUC/MIC monitoring, clinicians should conservatively target AUCs for 
patients with suspected or documented serious infections due to MRSA assuming a vancomycin 
MICBMD of 1 mg/L or less at most institutions. Given the importance of early, appropriate therapy, 
vancomycin targeted exposure should be achieved early during the course of therapy, preferably 
within the first 24 to 48 hours (A-II).  As such, the use of Bayesian-derived AUC monitoring may 
He pヴudeﾐt iﾐ these Iases siﾐIe it doesﾐ’t ヴeケuiヴe steady-state serum vancomycin concentrations 
to allow for early assessment of AUC target attainment. 
3. Trough only monitoring, with target between 15–20 mg/L, is no longer recommended based on 
efficacy and nephrotoxicity data in patients with serious infections due to MRSA (A-II).  There is 
insufficient evidence to provide recommendations on whether trough only or AUC-guided 
vancomycin monitoring should be used among patients with non-invasive MRSA or other 
infections.   
4. Vancomycin monitoring is recommended for patients receiving vancomycin for serious MRSA 
infections to achieve sustained targeted AUC (assuming a MICBMD of 1 mg/L, unless it is known to 
be greater or less than 1 mg/L by BMD).  Independent of MRSA infection, vancomycin monitoring 
is also recommended for all patients at high risk of nephrotoxicity (e.g., critically-ill patients 
receiving concurrent nephrotoxins), patients with unstable (i.e., deteriorating or significantly 
improving) renal function, and those receiving prolonged courses of therapy (more than three to 
five days).  We suggest the frequency of monitoring be based on clinical judgement; frequent or 
daily monitoring may be prudent for hemodynamically unstable patients (e.g., end stage renal 
disease) and once-weekly monitoring for hemodynamically stable patients (B-II).  
5. Based on current national vancomycin susceptibility surveillance data, under most circumstances 
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ﾏg/L, the pヴoHaHility of aIhie┗iﾐg aﾐ AUC/MIC д 4ヰヰ taヴget is uﾐlikely ┘ith Ioﾐ┗eﾐtioﾐal dosiﾐg; 
higher doses may risk unnecessary toxicity and the decision to change therapy should be based 
on clinical judgement. In addition, when MICBMD < 1 mg/L, we do not recommend decreasing the 
dose to achieve the AUC/MIC target.  It is important to note the limitations in automated 
susceptibility testing methods, including the lack of precision and variability in MIC results 
depending on method used (B-II). 
6. The pharmacokinetics of continuous infusion suggest that such regimens may be a reasonable 
alternative to conventional intermittent infusion dosing when the AUC target cannot be achieved 
(B-II).   
7. Incompatibility with vancomycin and other drugs commonly co-administered in the ICU requires 
the use of independent lines or multiple-catheters when vancomycin is being considered for 
continuous infusion (A-III). 
B.  ADULTS 
8. Given the narrow vancomycin AUC range for therapeutic effect and minimal acute kidney injury 
(AKI), the most accurate and optimal way to manage vancomycin dosing should be through AUC-
guided dosing and monitoring (A-II).  We recommend to accomplish this in one of two ways. 
a. One approach relies on the collection of two concentrations (obtained near steady-state, 
post-distributional peak concentration at 1-2 hours after infusion and trough at end of 
dosing interval) preferably but not required during the same dosing interval (if possible) 
and utilizing first-order pharmacokinetic (PK) equations to estimate the AUC (A-II).   
b. The preferred approach to monitor AUC involves the use of Bayesian software programs, 
embedded with a PK model based on richly sampled vancomycin data as the Bayesian 
prior, to optimize the delivery of vancomycin based on the collection of one or two 
vancomycin concentrations, with at least one trough.  It is preferred to obtain two PK 
samples (i.e., 1-2 hours post infusion and at end of dosing interval) to estimate the AUC 
with the Bayesian approach (A-II).  A trough concentration alone may be sufficient to 
estimate the AUC with the Bayesian approach in some patients, but more data are needed 
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9. Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an 
intermittent infusion are recommended for most patients with normal renal function when 
assuming MICBMD of 1 mg/L (A-II).  In patients with normal renal function, these doses may not 
achieve therapeutic AUC/MIC target when the MIC is 2 mg/L.  
10. Continuous Infusion: Based on current available data, a loading dose of 15-20mg/kg, followed by 
daily maintenance CI of 30-40mg/kg up to 60mg/kg, to achieve target steady-state concentration 
of 20-25mg/L may be considered for critically-ill patients (B-II).   AUC24 can be simply calculated 
when multiplying steady-state concentration (i.e., desired therapeutic range of 20-25 mg/L 
throughout entire dosing interval) by a factor of 24 (B-II).  Attaining the desired drug exposure 
may be more readily accomplished given the ease of sampling time and dosage adjustment by 
changing the rate of infusion which is a highly desirable feature in critically-ill patients (B-II). 
11. The risk of developing nephrotoxicity with continuous infusion appears to be similar or lower 
compared to intermittent dosing when targeting steady-state concentration 15-25 mg/L and 
trough 10-20 mg/L, respectively (B-II).  Definitive studies are needed to compare drug exposure 
based on measured AUC24 and factors that predispose to development of nephrotoxicity such as 
receipt of concomitant nephrotoxins, diuretics, and/or vasopressor therapy in patients receiving 
continuous infusion vs. intermittent infusion of vancomycin.  
12. In order to achieve rapid attainment of targeted concentrations in critically-ill patients with 
suspected or documented serious MRSA infections, a loading dose of 20-35 mg/kg can be 
considered for intermittent administration of vancomycin (B-II).  Loading doses should be based 
on actual body weight and not exceed 3000 mg.  More intensive and early therapeutic 
monitoring should also be performed in obese patients (B-II). 
13. Adult Obesity: A vancomycin loading dose of 20-25 mg/kg using actual body weight with a 
maximum of 3000 mg may be considered in obese adult patients with serious infections (B-II). 
Empiric maintenance doses for most obese patients usually do not exceed 4500 mg/day, 
depending on their renal function (B-II).  Early and frequent monitoring of AUC exposure is 
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14. Intermittent Hemodialysis: Since efficacy data are unavailable for AUC < 400 mg*hr/L, monitoring 
based on pre-dialysis serum concentrations and extrapolating these values to estimate AUC is 
most practical. Maintaining pre-dialysis concentrations between 15 and 20 mg/L are likely to 
achieve the AUC of 400-600 mg*hr/L in the previous 24 hours (C-III).  Pre-dialysis serum 
concentration monitoring should be performed not less than weekly and should drive 
subsequent dosing rather than a strict weight-based recommendation, although these 
recommended doses provide a useful starting point until serum concentrations have been 
determined (B-II).   
15. Hybrid Dialysis Therapies (e.g. Slow-Low Efficiency Dialysis [SLED]): Loading doses of 20-25 mg/kg 
actual body weight should be used, recognizing that these hybrid dialysis therapies efficiently 
remove vancomycin (B-III). Initial doses should not be delayed to wait for a dialysis treatment to 
end. Maintenance doses of 15 mg/kg should be given after hybrid hemodialysis ends or during 
the final 60-90 minutes of dialysis, as is done with standard hemodialysis (B-III). Concentration 
monitoring should guide further maintenance doses.   
16. Continuous Renal Replacement Therapies (CRRT): Loading doses of 20-25 mg/kg by actual body 
weight should be used in patients receiving CRRT at conventional, KDIGO-recommended effluent 
rates of 20-25 mL/kg/hr (B-II).  Initial maintenance dosing for CRRT with effluent rates of 20-25 
mL/kg/hr should be 7.5-10 mg/kg every 12 hours (B-II).  Maintenance dose and dosing interval 
should be based on serum concentration monitoring which should be conducted within the first 
24 hours to ensure AUC/MIC targets are met.  In fluid overloaded patients, doses may be reduced 
as patients become euvolemic and drug Vd decreases. The use of continuous infusion vancomycin 
in patients receiving CRRT appears to be growing, and could be used in place of intermittent 
vancomycin dosing, especially when high CRRT ultrafiltrate/dialysate flow rates are employed (B-
II).   
C.  PEDIATRICS 
17. Based on an AUC target of 400 mg*hr/L (Hut poteﾐtially up to 6ヰヰ ﾏg*hヴ/L assuﾏiﾐg MIC of г ヱ 
mg/L) from adult data, the initial recommended vancomycin dosage for children with normal 
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hour, for children ages 3 months and older (A-II).  
18. The maximum empiric daily dose is usually 3600 mg/day in children with adequate renal function 
(C-III).   Most children generally should not require more than 3000 mg/day and doses should be 
adjusted based on observed concentrations to achieve the AUC/MIC target.  Early monitoring of 
observed concentrations is recommended when doses exceed 2000 to 3000 mg/day (A-III).  
Furthermore, close monitoring of observed concentrations and renal function is prudent in 
patients with poor or augmented renal clearance as resolution of their renal function may occur 
within the first five days of therapy.   
19. AUC-guided therapeutic monitoring for vancomycin, preferably with Bayesian estimation, is 
suggested for all pediatric age groups, based on developmental changes of vancomycin CL 
documented from the newborn to the adolescent.  Based on current available data, the 
suggestion for AUC-guided monitoring in pediatrics aligns with the approach for adults, including 
the application of Bayesian estimation for one trough concentration, or first-order PK equations 
with two concentrations (B-II).  The Bayesian AUC-guided dosing strategy may be an optimal 
approach to individualize vancomycin therapy in pediatrics since it can incorporate varying ages, 
weights, and renal function.  Both serum concentrations of vancomycin and renal function should 
be monitored since vancomycin CL and creatinine CL are not always well correlated in pediatrics.  
Furthermore, aggressive dosing to maintain target AUC exposure and decrease the risk of 
potential AKI in treatment of MRSA infection necessitates drug monitoring.  
20. Therapeutic monitoring may begin within 24 to 48 hours of vancomycin therapy for serious MRSA 
infections in children, as in adults (B-III).  Any delay in therapeutic monitoring should be based on 
severity of infection and clinical judgment.  Dosing adjustment should be made for those with 
renal insufficiency, obesity, or for those receiving concurrent nephrotoxic drug therapy.   
Following the initial dose, dosing adjustment is important for those with acute renal insufficiency, 
but subsequent adjustment (particularly within the first 5 days of therapy) may be necessary for 
those experiencing recovery of renal function.  Sustained or subsequent decreases in dosage may 
be needed, particularly for those with chronic renal insufficiency and those receiving concurrent 
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21. Vancomycin exposure may be optimally maintained below the thresholds for AUC of 800 mg*hr/L 
and trough concentrations of 15 mg/L to minimize AKI (B-II).  The safety of vancomycin above 80 
mg/kg/day has not been prospectively evaluated.  Avoiding vancomycin doses  100 mg/kg/day 
is suggested since they are likely to surpass these thresholds (B-III). 
22. Insufficient data exist on which to base a recommendation for a loading dose among the non-
obese pediatric population.  Loading doses from adult studies may be considered, but further 
studies are needed to elucidate the appropriate dose for the various pediatric populations from 
the neonate to adolescent (C-III). 
23. Pediatric Obesity: Data suggest that obese children are likely to have vancomycin exposures that 
may be statistically greater than normal weight children when doses are calculated on a mg/kg 
basis, but these differences are not known to be of sufficient clinical importance to suggest 
different mg/kg empiric vancomycin dosages in obese children at this time.  Similar to non-obese 
children, obese children < 12 years old, compared with those д ヱヲ yeaヴs, ﾏay ヴeケuiヴe higheヴ 
mg/kg dose (B-II).   
24. Pediatric Obesity: Therapeutic monitoring is likely to be of particular value in obese children, both 
for therapeutic response and the risk of AKI.  The specific recommendations for therapeutic 
monitoring in non-obese children may also apply for obese children (B-II).  A loading dose of 20 
mg/kg by total body weight is recommended in obese children (A-III).   
25. Neonates: Doses recommended to achieve an AUC of 400 mg*hr/L (assuming an MIC of 1 mg/L) 
in neonates and infants up to 3 months old range from 10 to 20 mg/kg every 8 to 48 hours, 
depending on post-menstrual age, weight and SCr (A-II).    
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